Trial Profile
A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira vaccine in Healthy 'Adults' aged greater than or equal to 18 to less than 60 years and in Healthy 'Older Adults' aged greater than or equal to 60 years for the 2008/2009 Northern Hemisphere Influenza Season
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 May 2012
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Afluria) (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors CSL
- 04 Aug 2011 New trial record